These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1329286)

  • 1. Prevalence of clinically overt cytomegalovirus disease in kidney transplant patients.
    Mancilla E; Alberú J; Alessio-Robles L; Elizondo J; Reyes E; Sifuentes-Osornio J; Bordes-Aznar J
    Transplant Proc; 1992 Oct; 24(5):1919-20. PubMed ID: 1329286
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic rejection in kidney transplant patients receiving cytomegalovirus prophylaxis with acyclovir.
    Birkeland SA; Rohr N; Elbirk A; Jørgensen KA
    Transplant Proc; 1995 Jun; 27(3):2040-1. PubMed ID: 7792878
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
    Basri N; Abdullah KA; Shaheen FA
    Exp Clin Transplant; 2007 Jun; 5(1):601-3. PubMed ID: 17617050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors in an outbreak of Pneumocystis carinii in a transplant unit.
    Santiago-Delpín EA; Mora E; González ZA; Morales-Otero LA; Bermudez R
    Transplant Proc; 1988 Feb; 20(1 Suppl 1):462-5. PubMed ID: 2831643
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of cytomegalovirus gastrointestinal ulceration in a heart transplant patient.
    Sinnott JT; Cullison JP; Rogers K
    J Heart Transplant; 1987; 6(3):186-8. PubMed ID: 2821210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence, prevention and therapy of cytomegalovirus and pneumocystis carinii pneumonia after liver transplantation].
    Lauchart W
    Med Klin (Munich); 1992 Oct; 87 Suppl 1():60-4. PubMed ID: 1334223
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with oral acyclovir.
    Balfour HH; Fletcher CV; Dunn D
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):17-9. PubMed ID: 1647558
    [No Abstract]   [Full Text] [Related]  

  • 11. Infectious diseases in renal allograft recipients: new developments in therapy and prevention.
    Peterson PK; Simmons RL
    Transplant Proc; 1984 Aug; 16(4):1111-3. PubMed ID: 6087519
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical significance of positive cytomegalovirus cultures from urine and/or blood.
    Kokado Y; Takahara S; Takano Y; Kameoka H; Ishibashi M; Okuyama A; Tanaka K; Oosumi Y; Okada S; Sonoda T
    Transplant Proc; 1992 Aug; 24(4):1562-4. PubMed ID: 1323156
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
    Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral acyclovir therapy for cytomegalovirus infection after renal transplantation.
    Nunan TO; King M; Bull P; Banatvala JE; Jones NF; Hilton PJ
    Clin Nephrol; 1984 Jul; 22(1):28-31. PubMed ID: 6090044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of transplant rejection in the presence of cytomegalovirus viremia.
    O'Hair DP; Johnson CP; Roza AM; Adams MB
    Transplant Proc; 1990 Aug; 22(4):1815-7. PubMed ID: 2167537
    [No Abstract]   [Full Text] [Related]  

  • 16. DHPG treatment of kidney transplant recipients with severe CMV infection.
    Lang P; Buisson C; Rostoker G; Ben Maadi A; Fruchaud G; Deforge L; Chopin D; Abbou C; Romano P; Fleury J
    Transplant Proc; 1989 Feb; 21(1 Pt 2):2084-6. PubMed ID: 2540560
    [No Abstract]   [Full Text] [Related]  

  • 17. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
    Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
    Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of cytomegalovirus infections in renal transplant recipients with 9-(1,3-dihydroxy-2-propoxymethyl) guanine.
    Cantarovich M; Hiesse C; Lantz O; Fassi-Fihri S; Charpentier B; Fries D
    Transplantation; 1988 Jun; 45(6):1139-41. PubMed ID: 2837848
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical course of cytomegalovirus infection in renal transplant recipients].
    Luchsinger V; Suárez M; Montiel F; Kaltwasser G
    Rev Med Chil; 1999 Jan; 127(1):9-17. PubMed ID: 10436673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.